Aktienanalyse zu Savara Inc (SVRA)SVRASavara Inc

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Savara Inc is currently not a strong buy due to its recent price decline and negative indicators, despite a potential upside based on analyst targets. The current price is $5.26, which is significantly lower than the analyst price target of $11, suggesting a potential upside of 109%. However, the RSI is at 29.297, indicating the stock is oversold, and the company has a forward P/E ratio of 0.4076, which typically suggests undervaluation. The main risk is the ongoing negative net income trend, with losses expected to reach -$40.2 million in Q2 2026, which could impact investor confidence.

5 analysts cover SVRA: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 10.17.